儿童泛发性脓疱型银屑病发病机制及治疗进展

doi:10.12372/jcp.2025.24e1264

摘要/Abstract

摘要：

泛发性脓疱型银屑病（GPP）是一种罕见的、复发性的全身性炎症性皮肤病。白细胞介素（IL）-36RN（IL36RN）是GPP最常见的致病基因。由IL-1/IL-36-趋化因子-中性粒细胞轴介导的先天性免疫在GPP的发病机制中起核心作用，肿瘤坏死因子-α（TNF-α）/IL-23/IL-17介导的适应性免疫也参与GPP发病。阿维A、甲氨蝶呤、环孢素和生物制剂是目前GPP的主要治疗药物。大部分生物制剂在儿童GPP仍属于超适应证使用。越来越多证据表明，阿达木单抗和司库奇尤单抗治疗儿童GPP已取得较好疗效。IL-36受体抑制剂佩索利单抗是GPP新的治疗靶点，为GPP治疗和预防带来新的希望。文章就儿童GPP的发病机制和治疗进展进行综述，为该病的临床诊治提供参考。

关键词: 泛发性脓疱型银屑病, 发病机制, 治疗进展, 生物制剂, 儿童

Abstract:

Generalized pustular psoriasis (GPP) is a rare, recurrent systemic inflammatory skin disease. Interleukin (IL)-36RN (IL36RN) is the most common causative gene in GPP. Innate immunity mediated by IL-1/IL-36-chemokine-neutrophils plays a central role in the pathogenesis of GPP, and adaptive immunity mediated by tumor necrosis factor-α (TNF-α)/IL-23/IL-17 is also involved in GPP pathogenesis. At present, the main therapeutic agents for GPP are acitretin, methotrexate, cyclosporine and biologics. Most of the biologics are still used as over-indications in pediatric GPP. There is increasing evidence that adalimumab and secukinumab have achieved better efficacy in the treatment of GPP in children. Spesolimab, an IL-36 receptor inhibitor, is a new therapeutic target for GPP, bringing new hope for the treatment and prevention of GPP. This article reviews the pathogenesis and treatment progress of GPP in children, and provides reference for the clinical diagnosis and treatment of the disease.

Key words: generalized pustular psoriasis, pathogenesis, treatment progress, biologics, child

中图分类号:

吕明君, 罗文, 杨锦向, 梁键莹, 姚志荣. 儿童泛发性脓疱型银屑病发病机制及治疗进展[J]. 临床儿科杂志, 2025, 43(7): 556-562.

LYU Mingjun, LUO Wen, YANG Jinxiang, LIANG Jianying, YAO Zhirong. Progress in pathogenesis and treatment of pediatric generalized pustular psoriasis[J]. Journal of Clinical Pediatrics, 2025, 43(7): 556-562.

参考文献 39

[1]	Choon SE, van de Kerkhof P, Gudjonsson JE, et al. International consensus definition and diagnostic criteria for generalized pustular psoriasis from the international psoriasis council[J]. JAMA Dermatol, 2024, 160(7): 758-768. doi: 10.1001/jamadermatol.2024.0915 pmid: 38691347
[2]	Feng JN, Guo JZ, Zhang Q, et al. Higher prevalence of generalized pustular psoriasis in Asia? A population-based study using claim data in China and a systematic review[J]. Dermatology, 2023, 239(2): 195-205.
[3]	Choon SE, De La Cruz C, Wolf P, et al. Health-related quality of life in patients with generalized pustular psoriasis: a systematic literature review[J]. J Eur Acad Dermatol Venereol, 2024, 38(2): 265-280.
[4]	Zhao A, Li M. Understanding the pathogenesis of generalized pustular psoriasis based on molecular genetics and immunopathology[J]. Int J Dermatol Venereol, 2022, 5(4): 199-206.
[5]	Krueger JG, Pagotto A, Haftel S, et al. Targeted review of IL36RN mutations in patients with generalised pustular psoriasis[J]. Skin Health Dis, 2024, 4(2): e343.
[6]	Yoshikawa T, Takeichi T, Nishida K, et al. MEFV variants are a predisposing factor for generalized pustular psoriasis[J]. J Am Acad Dermatol, 2024, 90(4): 852-854.
[7]	Chen J, Xue X, Wang Z, et al. Genetic analysis of different subtypes of aseptic pustulosis in the Chinese population[J]. Clin Exp Dermatol, 2024, 49(10): 1217-1226.
[8]	Choon SE, Foley PA, Asawanonda P, et al. Asia-Pacific consensus recommendations on the management of generalized pustular psoriasis[J]. J Dermatol, 2024, 51(12): 1579-1595.
[9]	Wang Z, Xiang X, Chen Y, et al. Different clinical features of pediatric generalized pustular psoriasis in patients with or without IL36RN variants[J]. Dermatology, 2023, 239(2): 217-226.
[10]	Uppala R, Tsoi LC, Harms PW, et al. "Autoinflammatory psoriasis"-genetics and biology of pustular psoriasis[J]. Cell Mol Immunol, 2021, 18(2): 307-317.
[11]	Sugiura K, Fujita H, Komine M, et al. The role of interleukin-36 in health and disease states[J]. J Eur Acad Dermatol Venereol, 2024, 38(10): 1910-1925. doi: 10.1111/jdv.19935 pmid: 38779986
[12]	Lan Y, Wu X, Zhong X, et al. Increased neutrophil-derived IL-17A identified in generalized pustular psoriasis[J]. Exp Dermatol, 2024, 33(2): e15026.
[13]	Kodali N, Blanchard I, Kunamneni S, et al. Current management of generalized pustular psoriasis[J]. Exp Dermatol, 2023, 32(8): 1204-1218.
[14]	Lu J, Yu Q, Huang D, et al. Spesolimab rapidly treats generalized pustular psoriasis and improves the skin immune microenvironment in Chinese patients[J]. Clin Immunol, 2024, 265: 110280.
[15]	Hospach T, Glowatzki F, Blankenburg F, et al. Scoping review of biological treatment of deficiency of interleukin-36 receptor antagonist (DITRA) in children and adolescents[J]. Pediatr Rheumatol Online J, 2019, 17(1): 37. doi: 10.1186/s12969-019-0338-1 pmid: 31286990
[16]	Menter A, Cordoro KM, Davis D, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients[J]. J Am Acad Dermatol, 2020, 82(1): 161-201. doi: S0190-9622(19)32655-6 pmid: 31703821
[17]	《脓疱型银屑病诊疗中国专家共识(2022版) 》编写委员会专家组. 脓疱型银屑病诊疗中国专家共识(2022版)[J]. 中华皮肤科杂志, 2022, 55(3): 187-195.
	Writing committee expert group on "diagnosis and treatment of pustular psoriasis: a Chinese expert consensus statement". Diagnosis and treatment of pustular psoriasis: a Chinese expert consensus statement (2022)[J]. Zhonghua Pifuke Zazhi, 2022, 55(3): 187-195.
[18]	Fujita H, Terui T, Hayama K, et al. Japanese guidelines for the management and treatment of generalized pustular psoriasis: the new pathogenesis and treatment of GPP[J]. J Dermatol, 2018, 45(11): 1235-1270.
[19]	Miao C, Chen Y, Wang Z, et al. Real-world data on the use of secukinumab and acitretin in pediatric generalized pustular psoriasis[J]. J Dermatol, 2023, 50(2): 258-261.
[20]	王雅辰, 王召阳, 向欣, 等. 口服阿维A对106例儿童身高和骨骼发育影响的回顾性分析[J]. 中华皮肤科杂志, 2022, 55(12): 1073-1077.
	Wang YC, Wang ZY, Xiang X, et al. Effect of oral acitretin on the height and bone development of children: a retrospective analysis of 106 cases[J]. Zhonghua Pifuke Zazhi, 2022, 55(12): 1073-1077.
[21]	宋璞, 马翠玲, 樊平申, 等. 环孢素治疗儿童泛发性脓疱性银屑病临床疗效的回顾性分析[J]. 临床皮肤科杂志, 2022, 51(6): 369-372.
	Song P, Ma CL, Fan PS, et al. Clinical experience with systemic cyclosporine A treatment for childhood generalized pustular psoriasis[J]. Linchuang Pifuke Zazhi, 2022, 51(6): 369-372.
[22]	张娜, 李税琪, 李红文. 环孢素A治疗儿童泛发性脓疱型银屑病的临床效果[J]. 河南医学研究, 2020, 29(15): 2727-2729.
	Zhang N, Li SQ, Li HW. Efficacy on cyclosporine A in the treatment of childhood generalized pustule psoriasis[J]. Henan Yixue Yanjiu, 2020, 29(15): 2727-2729.
[23]	中华医学会皮肤性病学分会, 中国医师协会皮肤科医师分会, 中国中西医结合学会皮肤性病专业委员会. 中国银屑病生物制剂及小分子药物治疗指南(2024版)[J]. 中华皮肤科杂志, 2024, 57(11): 976-997.
	Chinese Society of Dermatology, China Dermatologist Association, Dermatology & Venereology Specialized Committee of Chinese Association of Integrative Medicine. Guidelines for the treatment of psoriasis with biologics and small-molecule drugs in China (2024)[J]. Zhonghua Pifuke Zazhi, 2024, 57(11): 976-997.
[24]	Du Y, Yan Q, Chen M, et al. Efficacy of adalimumab in pediatric generalized pustular psoriasis: case series and literature review[J]. J Dermatolog Treat, 2022, 33(6): 2862-2868.
[25]	Arasiewicz H, Lesiak A, Dec M, et al. Successful treatment of a child's generalized pustular psoriasis with adalimumab in combination with low-dose acitretin[J]. Postepy Dermatol Alergol, 2023, 40(3): 464-466.
[26]	廉佳, 陈立新, 王莹, 等. 阿达木单抗联合阿维A治疗5例儿童泛发性脓疱型银屑病回顾性分析[J]. 中华皮肤科杂志, 2022, 55(10): 916-918.
	Lian J, Chen LX, Wang Y, et al. Adalimumab combined with acitretin in the treatment of five children with generalized pustular psoriasis: a retrospective clinical observation[J]. Zhonghua Pifuke Zazhi, 2022, 55(10): 916-918.
[27]	Liao K, Hou Z, Jing R, et al. Paediatric generalised pustular psoriasis with IL36RN mutation: successful treatment with adalimumab[J]. Indian J Dermatol, 2023, 68(6): 727.
[28]	Saikaly SK, Mattes M. Biologics and pediatric generalized pustular psoriasis: an emerging therapeutic trend[J]. Cureus, 2016, 8(6): e652.
[29]	Mazzotta A, Saraceno R, Esposito M, et al. Etanercept, childhood and long-term safety: a case of five years treatment[J]. Eur J Dermatol, 2011, 21(5): 776-777. doi: 10.1684/ejd.2011.1432 pmid: 21697062
[30]	Cuperus E, Koevoets R, van der Smagt JJ, et al. Juvenile interleukin-36 receptor antagonist deficiency (DITRA) with c.80T>C (p.Leu27Pro) mutation successfully treated with etanercept and acitretin[J]. JAAD Case Rep, 2018, 4(2): 192-195. doi: 10.1016/j.jdcr.2017.08.019 pmid: 29892664
[31]	Lu J, Li Y, Yu N, et al. Successful treatment of juvenile generalized pustular psoriasis with infliximab therapy: two case reports[J]. J Int Med Res, 2020, 48(3): 300060520912091.
[32]	孙志琳, 刘子莲, 许媛媛, 等. 英夫利西单抗治疗青少年急性泛发性脓疱型银屑病1例[J]. 中华皮肤科杂志, 2023, 56(1): 69-70.
	Sun ZL, Liu ZL, Xu YY, et al. A case of acute juvenile generalized pustular psoriasis successfully treated with infliximab[J]. Zhonghua Pifuke Zazhi, 2023, 56(1): 69-70.
[33]	Pan J, Qiu L, Xiao T, et al. Juvenile generalized pustular psoriasis with IL36RN mutation treated with short-term infliximab[J]. Dermatol Ther, 2016, 29(3): 164-167.
[34]	Wei K, Li P, He X, et al. Clinical efficacy and safety of secukinumab in the treatment of generalized pustular psoriasis in the pediatric population: a systematic review of the literature[J]. Front Med (Lausanne), 2024, 11: 1377381.
[35]	余敏, 应掌红. 司库奇尤单抗治疗儿童泛发性脓疱型银屑病临床分析[J]. 皮肤性病诊疗学杂志, 2024, 31(4): 226-231. doi: 10.3969/j.issn.1674-8468.2024.04.002
	Yu M, Ying ZH. Clinical analysis of secukinumab in the treatment of childhood generalized pustular psoriasis[J]. Pifuxingbing Zhenliaoxue Zazhi, 2024, 31(4): 226-231.
[36]	López-Sánchez C, Falla LM, Roé-Crespo E, et al. Excellent response to secukinumab in an infant with severe generalized pustular psoriasis[J]. J Dermatol, 2021, 48(6): 907-910.
[37]	Guevara B, Aquino J, Diaz R, et al. Infantile generalized pustular psoriasis with excellent response to secukinumab: a case report[J]. Exp Dermatol, 2023, 32(8): 1296-1298.
[38]	Chen Y, Wang Z, Liang Y, et al. Successful treatment of pediatric generalized pustular psoriasis (GPP) with spesolimab: 5 case reports and evaluations of circulating IL-36 levels[J]. J Inflamm Res, 2024, 17: 8199-8206. doi: 10.2147/JIR.S485077 pmid: 39525315
[39]	Pathak GN, Wang E, Dhillon J, et al. Spesolimab: a review of the first IL-36 blocker approved for generalized pustular psoriasis[J]. Ann Pharmacother, 2024, 307013968.